Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
2015 · The Lancet Oncology · 242 citations
https://doi.org/10.1016/s1470-2045(15)70198-1
K
Kate Fife
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
127
Papers
5.4K
Citations
30
h-index
50
i10-index
Kate Fife is an academic researcher from University of Cambridge. The author has contributed to research in topics: Renal cell carcinoma treatment & Cancer Genomics and Diagnostics & Renal and related cancers. The author has an h-index of 30, co-authored 108 publications.
ORCID: 0000-0002-1880-9049Papers by this author
worksBritish Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021*
2021 · British Journal of Dermatology · 100 citations
https://doi.org/10.1111/bjd.20524
Selection of Oncogenic Mutant Clones in Normal Human Skin Varies with Body Site
2020 · Cancer Discovery · 99 citations
https://doi.org/10.1158/2159-8290.cd-20-1092
Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective
2014 · British Journal of Cancer · 92 citations
https://doi.org/10.1038/bjc.2014.270
Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data
2019 · Targeted Oncology · 62 citations
https://doi.org/10.1007/s11523-019-00653-5
Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma
2016 · Future Oncology · 33 citations
https://doi.org/10.2217/fon-2016-0296
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat